|
1
|
Corrin B, Wick MR, Chang YL, et al:
Sarcomatoid carcinoma. Pathology and Genetics, Tumors of the Lung,
Pleura, Thymus and Heart, World Health Organization Classification
of Tumours. Travis WD, Brambilla E, Müller-Hermelink HK and Harris
CC: IARC Press; Lyon: pp. 53–58. 2004
|
|
2
|
Wick MR, Ritter JH and Humphrey PA:
Sarcomatoid carcinomas of the lung: a clinicopathologic review. Am
J Clin Pathol. 108:40–53. 1997.PubMed/NCBI
|
|
3
|
Mochizuki T, Ishii G, Nagai K, et al:
Pleomorphic carcinoma of the lung. Clinicopathologic
characteristics of 70 cases. Am J Surg Pathol. 32:1727–1735. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Przygodzki RM, Koss MN, Moran CA, et al:
Pleomorphic (giant and spindle cell) carcinoma is genetically
distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2
and p53 analysis. Am J Clin Pathol. 106:487–492. 1996.PubMed/NCBI
|
|
5
|
Bremnes RM, Veve R, Hirsch FR and Franklin
WA: The E-cadherin cell-cell adhesion complex and lung cancer
invasion, metastasis, and prognosis. Lung Cancer. 36:115–124. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Charalabopoulos K, Gogali A, Kostoula OK
and Constantopoulos SH: Cadherin superfamily of adhesion molecules
in primary lung cancer. Exp Oncol. 26:256–260. 2004.PubMed/NCBI
|
|
7
|
Jeanes A, Gottardi CJ and Yap AS:
Cadherins and cancer: how does cadherin dysfunction promote tumor
progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Makrilla N, Kollias A, Manolopoulos L and
Syrigos K: Cell adhesion molecules: role and clinical significance
in cancer. Cancer Invest. 27:1023–1037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nieman MT, Prudoff RS, Johnson KR and
Wheelock MJ: N-cadherin promotes motility in human breast cancer
cells regardless of their E-cadherin expression. J Cell Biol.
147:631–644. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li G, Satyamoorthy K and Herlyn M:
N-cadherin-mediated intercellular interactions promote survival and
migration of melanoma cells. Cancer Res. 61:3819–3825.
2001.PubMed/NCBI
|
|
12
|
Cavallaro U: N-cadherin as an invasion
promoter: a novel target for antitumor therapy? Curr Opin Investig
Drugs. 5:1274–1278. 2004.PubMed/NCBI
|
|
13
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1976:75–90. 2009.PubMed/NCBI
|
|
14
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iwatsuki M, Mimori K, Yokobori T, et al:
Epithelial-mesenchymal transition in cancer development and its
clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rees JRE, Onwuegbusi BA, Save VE, Alderson
D and Fitzgerald RC: In vivo and in vitro evidence for transforming
growth factor-β1-mediated epithelial to mesenchymal transition in
esophageal adenocarcinoma. Cancer Res. 66:9583–9590. 2006.
|
|
17
|
Kaimori A, Potter J, Kaimori JY, Wang C,
Mezey E and Koteish A: Transforming growth factor-β1 induces an
epithelial-to-mesenchymal transition state in mouse hepatocytes in
vitro. J Biol Chem. 282:22089–22101. 2007.
|
|
18
|
Takanami I, Imamura T, Hashizume T,
Kikuchi K, Yamamoto Y and Kodaira S: Transforming growth factor-β1
as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol.
47:1098–1100. 1994.
|
|
19
|
Takanami I, Imamura T, Hashizume T,
Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S: Expression of
PDGF, IGF-II and TGF-β1 in pulmonary adnocarcinoma. Pathol Res
Pract. 192:1113–1120. 1996.
|
|
20
|
Robson H, Anderson E, James RD and
Schofield RF: Transforming growth factor β1 expression in human
colorectal tumours: an independent prognostic marker in a subgroup
of poor prognosis patients. Br J Cancer. 74:753–758. 1996.
|
|
21
|
Saito H, Tsujitani S, Oka S, Kondo A,
Ikeguchi M, Maeta M and Kaibara N: The expression of transforming
growth factor-β1 is significantly correlated with the expression of
vascular endothelial growth factor and poor prognosis of patients
with advanced gastric carcinoma. Cancer. 86:1455–1462. 1999.
|
|
22
|
Desruisseau S, Palmari J, Giusti C, Romain
S, Martin PM and Berthois Y: Determination of TGF β1 protein level
in human primary breast cancers and its relationship with survival.
Br J Cancer. 94:239–246. 2006.
|
|
23
|
Pelosi G, Scarpa A, Manzotti M, et al:
K-ras gene mutational analysis supports a monoclonal origin of
biphasic pleomorphic carcinoma of the lung. Mod Pathol. 17:538–546.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakashima T, Huang C, Liu D, et al:
Neural-cadherin expression associated with angiogenesis in
non-small-cell lung cancer patients. Br J Cancer. 88:1727–1733.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zynger DL, Dimov ND, Ho LC, Laskin WB and
Yeldandi AV: Differential expression of neural-cadherin in
pulmonary epithelial tumours. Histopathology. 52:348–354. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kase S, Sugio K, Yamazaki K, Okamoto T,
Yano T and Sugimachi K: Expression of E-cadherin and β-catenin in
human non-small cell lung cancer and the clinical significance.
Clin Cancer Res. 6:4789–4796. 2000.
|
|
27
|
Nozawa N, Hashimoto S, Nakashima Y, et al:
Immunohistochemical α- and β-catenin and E-cadherin expression and
their clinicopathological significance in human lung
adenocarcinoma. Pathol Res Pract. 202:639–650. 2006.
|
